Author

S. Ottilie

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 3 Biochemistry· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 4 Approach:experimental assay· 3 Organism:mouse· 2 Approach:genetic perturbation / CRISPR· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Assay:metabolomics· 1 Organism:plant (other)· 1

Frequent Co-Authors

E. A. Winzeler· 4 shared F. Rocamora· 2 shared G. M. LaMonte· 2 shared M. R. Luth· 2 shared A. F. Cowman· 1 shared A. Horatscheck· 1 shared A. J. O'Donoghue· 1 shared A. K. Lukens· 1 shared

Activity by Year

2019-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 23 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersMicrobiology

E. A. Winzeler

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Development of Highly Selective Epoxyketone-based Plasmodium Proteasome Inhibitors with Negligible Cytotoxicity

J. Almaliti, P. Fajtova, J. Calla, G. M. LaMonte, M. Feng, F. Rocamora, S. Ottilie, E. Glukhov, E. Boura, R. T. Suhandynata, J. D. Momper, M. K. Gilson, E. A. Winzeler, W. H. Gerwick, A. J. O'Donoghue

This study develops highly selective epoxyketone-based proteasome inhibitors effective against Plasmodium falciparum with low cytotoxicity to human cells.

bioRxiv · Aug 6, 2022 · PreprintBiochemistry

Collateral sensitivity as a strategy to suppress resistance emergence: the challenge of diverse evolutionary pathways

R. E. K. Mandt, M. R. Luth, M. A. Tye, R. Mazitschek, S. Ottilie, E. A. Winzeler, M. J. Lafuente-Monasterio, F. J. Gamo, D. F. Wirth, A. K. Lukens

This study investigates collateral sensitivity between DHODH inhibitors to suppress malaria resistance, finding that cross-resistant mutants can emerge despite initial sensitivity.

bioRxiv · Apr 7, 2022Microbiology

Multistage and transmission-blocking targeted antimalarials discovered from the open-source MMV Pandemic Response Box

J. Reader, M. E. van der Watt, D. Taylor, C. Le Manach, N. Mittal, S. Ottilie, A. Theron, P. Moyo, E. Erlank, L. Nardini, N. Venter, S. Lauterbach, B. Bezuidenhout, A. Horatscheck, A. van Heerden, , L.-M. Birkholtz

The paper screens a compound library to identify antimalarial compounds active against multiple Plasmodium life stages and transmission-blocking agents.

bioRxiv · Jun 5, 2020Microbiology

Pan-active imidazolopiperazine antimalarials target the Plasmodium falciparum intracellular secretory pathway

G. M. LaMonte, D. S. Marapana, N. Gnadig, S. Ottilie, M. R. Luth, T. S. Worgall, F. Rocamora, G. M. Goldgof, R. Mohunlal, T. R. S. Kumar, J. K. Thompson, E. Vigil, J. Yang, D. Hutson, T. Johnson, , E. A. Winzeler

This study identifies imidazolopiperazines as targeting the Plasmodium falciparum secretory pathway by inhibiting protein trafficking and ER expansion.

bioRxiv · Aug 15, 2019Microbiology